Product news from the 09/26/06 News Brief

Share this article:
Allergan, maker of Botox cosmetic (Botulinum Toxin Type A), today announced it is launching its “next-generation” hyaluronic acid dermal filler products, Juvederm Ultra and Juvederm Ultra Plus. The launch will take place through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January 2007. Allergan will begin accepting physician pre-orders for the products on Nov.1 via its nationwide sales force. The FDA approved Connetics’ Verdeso (desonide) foam for the treatment of mild-to-moderate atopic dermatitis. Verdeso, previously referred to as Desilux, is a low-potency topical steroid. Connetics expects to begin marketing Verdeso to physicians in the fourth quarter of 2006 in 50g and 100g trade unit sizes. The FDA has approved new formulation of Alcon’s Travatan Z opthalmic solution for the expanded indication of reduction of elevated intraocular pressure. The drug is recommended for patients with open-angle glaucoma or ocular hypertension, who are intolerant of or not responsive enough to other medications.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.